More on KLRS

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (8.9 Score)

Upcoming Events

- Earnings (11/18/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Kalaris Therapeutics (NQ:KLRS)
Delayed: 1.80 -0.07 (3.74%)
Prev. Close $1.87  
Open$1.89 
52 Wk High$ 
52 Wk Low$ 
Day High$1.90 
Day Low$1.78 
P/E N/A  
EPS$ 
Volume36,034 

Friends, Peers and Foes (?): IMRX PEPG (more...)

Aug 11, 2026 09:34 AM Kalaris Therapeutics (KLRS) Tops Q2 EPS by 2c
Aug 11, 2026 08:00 AM Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
Jul 20, 2026 08:00 AM Kalaris Therapeutics names Liisa Bayko as CFO
Jul 20, 2026 08:00 AM Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer
Jul 17, 2026 07:00 AM Kalaris reports positive TH103 Phase 1a data in neovascular AMD
Jul 17, 2026 07:00 AM Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Jul 6, 2026 04:05 PM Kalaris Therapeutics names Laurie Keating to its board
Jul 6, 2026 04:05 PM Kalaris Appoints Laurie Keating to Board of Directors
Jun 23, 2026 08:00 AM Kalaris to present TH103 Phase 1a data at retina specialists meeting
Jun 23, 2026 08:00 AM Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
View All Articles

Entities mentioned with KLRS

View All Entities